The company said the breach is expected to disrupt operations and limit access to some products, with no timeline yet for restoring affected systems or products.
The move stood out in a broader earnings-driven premarket session that also hit software and retail names, underscoring that Boston Scientific’s decline was tied to an operational security issue rather than quarterly results.
The disclosure raises near-term questions about supply continuity and customer access as healthcare companies face growing pressure to contain cyber risks without interrupting product availability.